Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 8Completed 7Unknown 1Suspended 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 503Breast 39Gastrointestinal 30Gynecologic 26Thoracic 22Dermatologic 13Head & Neck 12Sarcoma 7Lymphoid 7Plasma cell 5Other hematologic neoplasm 5CNS 4Other solid neoplasm 2Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 51Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 8Small Cell Lung Carcinoma 6Adenoma, Islet Cell 6Colorectal Neoplasms 4Cholangiocarcinoma 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Carcinoid Tumor 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Salivary Gland Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Brain Neoplasms 2Biliary Tract Neoplasms 2Vulvar Neoplasms 1Vipoma 1Urinary Bladder Neoplasms 1Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Thymus Neoplasms 1Testicular Neoplasms 1

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × NET × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡